Last reviewed · How we verify

NCT04961398

Evaluation of Heidelberg Engineering SPECTRALIS OCT Signal to Noise Ratio Effect on Parameter Measurements

Completed Last updated 16 September 2025
What this trial tests

trial testing OCT imaging in Normal Eyes in 9 participants. Completed in 24 June 2021.

Timeline
21 June 2021
Primary endpoint
24 June 2021
24 June 2021

Quick facts

Lead sponsorHeidelberg Engineering GmbH
StatusCompleted
Study typeOBSERVATIONAL
Enrollment9
Start date21 June 2021
Primary completion24 June 2021
Estimated completion24 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Heidelberg Engineering GmbH

Who can join

22 and older, any sex, with Normal Eyes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of effect of various OCT scan speeds and filters on parameter measurements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of OCT imaging

Trials testing the same drug.

Other recruiting trials for Normal Eyes

Currently open trials in the same condition.

Other Heidelberg Engineering GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04961398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing